GROBio is developing promising new treatment modalities for reversing autoimmune disease.
Awaken Capital
风险投资与私募股权管理人
Investing in tech-enabled platforms and the entrepreneurs who build them.
关于我们
Awaken Capital is an early-stage venture capital firm investing in AI-enabled platforms and the entrepreneurs who build them. This means that instead of investing in a single molecule, material, or new therapy, we invest in the platforms used to create them. While vertical plays and industry-specific solutions can produce great returns, we find that truly nonlinear outcomes come from a platform-based approach. From machine intelligence and precision agriculture to material informatics and computational drug discovery, we identify and enable companies creating products that address large-scale problems in multiple markets. We believe that AI-enabled platforms will power the most successful companies of our time.
- 所属行业
- 风险投资与私募股权管理人
- 规模
- 2-10 人
- 类型
- 私人持股
Awaken Capital员工
动态
-
Like language, DNA is code. This is the basis for Ginkgo Bioworks and Google's partnership to harness AI for biology.
How Ginkgo Bioworks is teaching AI to speak DNA and transform bioengineering
Awaken Capital，发布于领英
-
People spanning boundaries creates new insights and new opportunities!
Expanding realms: Synthetic biology meets therapeutics
Awaken Capital，发布于领英
-
Highlighting the promise and potential of A-Alpha Bio's platform to improve human health.
Unleashing the power of collaboration: A-Alpha Bio and Amgen expand partnership to advance molecular glue discovery
Awaken Capital，发布于领英
-
We are proud to see what 3T Biosciences has accomplished in their partnership with Boehringer Ingelheim and excited for what may lie ahead.
3T Biosciences announces second cancer immunotherapy partnership with Boehringer Ingelheim
Awaken Capital，发布于领英